University of Maine Researchers Develop Sustainable Wood-Based Production Method for Key Pharmaceutical Building Block
Key Insights
Researchers at the University of Maine Forest Bioproducts Research Institute (search) have developed a sustainable method to produce (S)-3-hydroxy-γ-butyrolactone (search) (HBL) from wood biomass-derived glucose, potentially reducing pharmaceutical manufacturing costs.
The new process reduces production costs by more than 60% compared to current petroleum-based methods while significantly lowering greenhouse gas emissions.
HBL serves as a crucial chiral building block for synthesizing expensive medications including statins (search), antibiotics (search), and HIV inhibitors (search).
Researchers at the University of Maine Forest Bioproducts Research Institute (search) (FBRI) have developed a breakthrough sustainable method to produce a key pharmaceutical ingredient from wood biomass, potentially offering a solution to high prescription drug costs in the United States. The new process converts glucose derived from woody biomass into (S)-3-hydroxy-γ-butyrolactone (search) (HBL), a crucial building block used in manufacturing expensive medications.
Cost-Effective Alternative to Petroleum-Based Production
The innovative approach addresses one of the main factors driving pharmaceutical prices: the high cost of production materials. According to the research published in Chem, the new method reduces production costs by more than 60% compared to current methods that rely on petroleum-derived feedstocks. The process also significantly reduces greenhouse gas emissions while maintaining high concentrations and yields.
"The competing processes either lead to low yields, use hazardous starting materials or are just generally costly because of the chosen production scheme and low output," said Thomas Schwartz, associate director of FBRI and associate professor in the Maine College of Engineering and Computing, who served as a lead author for the study. "The commercial process is expensive because you have to add the chiral center to the molecule, which doesn't occur naturally with most petrochemicals."
Critical Role in High-Value Pharmaceutical Manufacturing
HBL represents a chiral species essential for synthesizing an array of crucial medications, including statins (search) for cholesterol management, antibiotics (search), and HIV inhibitors (search). Chirality, a molecular property where compounds cannot be superimposed with their mirror images, directly influences a drug's biological effects, including efficacy, side effects, and metabolization patterns.
The high cost of chiral drugs stems largely from the expensive building blocks required during synthesis, which involve complex reaction and purification pathways. Among the most expensive medications are those requiring chiral centers, making cost-effective production methods particularly valuable for the pharmaceutical industry.
Sustainable Feedstock Utilization
The process leverages glucose that can be derived from any lignocellulosic feedstock, including wood chips, sawdust, tree branches, and other woody biomass materials. This approach opens new possibilities for sustainable pharmaceutical ingredient production while utilizing readily available forestry byproducts.
"If we use other kinds of wood sugars, like xylose that is an unneeded byproduct from making pulp and paper, we expect that we could produce new chemicals and building blocks, like green cleaning products or new renewable, recyclable plastics," Schwartz explained.
Addressing Previous Production Challenges
The U.S. Department of Energy (search) has identified HBL as a highly valuable precursor to various chemicals and plastics. However, previous attempts to produce HBL sustainably achieved only limited success due to safety issues, ineffectiveness, or lack of cost-efficiency. The FBRI research team's approach overcomes these historical limitations while providing additional economic opportunities through the co-production of other commercially important chemicals, such as glycolic acid.
The breakthrough represents a significant advancement in sustainable pharmaceutical manufacturing, potentially transforming how the industry approaches the production of chiral building blocks essential for life-saving medications.